Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus \geq10$ 10 g/dL : an exploratory analysis of a phase 3 trial

Autor: Canon, Jean-Luc, Vansteenkiste, Johan, Hedenus, Michael, Gascon, Pere, Bokemeyer, Carsten, Ludwig, Heinz, Vermorken, Jan Baptist, Legg, Jason, Pujol, Beatriz, Bridges, Ken
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Zdroj: Medical oncology
ISSN: 1357-0560
Popis: Darbepoetin alfa (DA) is an erythropoiesisstimulating agent (ESA) approved for treating chemotherapy-induced anemia (CIA). Safety concerns have prompted changes to the ESA-product information, which now recommends initiating ESAs at hemoglobin (Hb) levels = 10 g/dL (n = 354). The Q3 W and QW groups were combined. Transfusion rates were highest in the = 10 g/dL was 68% (59, 78) and 88% (82, 92) in the = 1 g/dL-Hb rise in 14 days progressively decreased. Incidence of venous thromboembolic events was similar in all baseline-Hb groups and similar between patients with or without a >= 1 g/dL-Hb rise in 14 days. Overall, transfusion risk increased and Hb response decreased at lower baseline-Hb levels in this exploratory analysis. When following ESA-product information to initiate ESAs at Hb
Databáze: OpenAIRE
Externí odkaz: